In light of this, Jennifer Carew and coauthors concluded that targeting BET-proteins and HDAC6 together could improve the antitumor properties of the BET-inhibitor against multiple myeloma, which was further confirmed by in vitro and in vivo studies [39]. This evidence concerns the gene DNER and plasma cell myeloma.